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Using a radioimmunoassay peeitic for porcine glicentin C-terminal hexapeptide, we isolated apeptide from 
porcine pancreas and characterized it as the C-terminal 64-69 sequence of glicentin: H-Asn-Lys-Asn-Asn- 
Ile-Ala-OH. The purification steps included gel liltration, ion-exchange chromatography and HPLC. In 
each step, the recovery of the desired peptide, radioimmunologically estimated from the respective elution 
profile, was 71.4-91.7x. The final yield of the hexapeptide was 22 pg (4.3 %) from 800 g pancreas. The 
pancreatic content of this peptide was estimated tohe approximately equimolar to that of pancreatic gluca- 
gon. No hexapeptidelibe component was detected in porcine intestinal extracts. The data confirmed that 
the processing ofpancreatic proglucagon liberates the C-terminal hexapeptide of the intramolecular glicen- 
tin sequence ina tissue-specific marmer during the production of glucagon. 
~Iicent~ (64-69) ~0gIu~agon Isolation ~~io~rn~o~say Sequence analysis 
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1. INTRODUCTION 
Glicentin, a 69 residue polypeptide, has been 
isolated from porcine small intestine as a major 
component of gut glucagon-like immunoreactants 
(gut GLIs) [l]. The peptide contains the entire se- 
quence of glucagon in positions 33-61 which is ex- 
tended at the N-terminus via Lys-Arg with the 
l-30 sequence, ~ucagon-related pancreatic pep- 
tide (GRPP), and at the C-terminus via Lys-Arg 
with a hexapeptide (positions 64-69) 121. 
Nucleotide sequence analysis of the cloned cDNA 
or the gene encoding mammalian pancreatic 
glucagon revealed the presence of a glicentin se- 
quence in the N-terminal portion of the precursor 
protein, preproglucagon [3-61. Isolation of GRPP 
from porcine pancreas [7] supported the concept 
of proteolytic cleavage of the glicentin sequence 
from the precursor molecule to produce glucagon 
in the pancreas, Here we describe the isolation of 
* To whom correspondence should be addressed 
a hexapeptide from porcine pancreas and its 
chemical characterization as the C-terminal 64-69 
sequence of glicentin. 
2. MATERIALS AND METHODS 
High-performance liquid chromatography 
(HPLC) was performed on a Toyo-Soda SP8700 
high-speed liquid ~hromatograph and the eluates 
were monitored with a Toyo-Soda UV-8-11 spec- 
trophotometer at 210 nm wavelength. Amino acid 
analysis was carried out with a Hitachi 835 amino 
acid analyzer using o-phthalaldehyde. Peptide se- 
quence analysis was performed on an Applied 
Biosystems 470A gas-phase protein sequencer con- 
nected to a Beckman HPLC instrument. The 
reagents used included acetonitrile and water for 
HPLC (Merck, Darmstadt), the reagents for se- 
quence analysis (Applied Biosystems, Foster City, 
CA) and for peptide synthesis (Protein Research 
Foundation, Osaka). The synthetic porcine 
glicentin-related peptides used in this study were 
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prepared by conventional solution methodology 
[g]. Purity of the synthetic peptides was assessed 
extensively by routine anafytid criteria. Detaik of 
the synthesis wiff be described elsewhere. 
2.1 e ~~di~i~~~~~as~ay 
Radioimmunoassay specific for glicentin C- 
terminal hexapeptide was performed as described 
[9]. In brief: 4-(3-hydroxyphenyl)propionylglicen- 
tin(62-69) [HPP-glicentin(62-69)] was radioiodi- 
nated by the chloramine T method and purified by 
gel filtration on Sephadex G-10; antigen-antibody 
reaction was carried out using anti-glicentin- 
(49-69) serum R4804, ‘~~I-HPP-g~ce~tin(62~9) 
as tracer and synthetic ~icen~in(~-69) as stand- 
ard; anti~dy-bound antigen was separated from 
free antigen by dextran-coated charcoal. Relative 
crossreactivities of various porcine glicentin- 
related peptides in the radioimmunoassay are 
shown in table 1. 
Pancreatic glucagon specific radioimmunoassay 
was carried out as described [lo] using antisera 
OAL123. 
Table 1 
Relative crossreactivities of synthetic and natural 
porcine glicentin-related peptides in glicentin C-terminal 
hexapeptide specific radi~~muno~~ay 
Peptide Relative crossreactivity 
Synthetic peptides 
Glicentin(64-69) accepted as 
100 
Glicentin(62-69) 89.3 
HPP-glicentin(62-69) 91.5 
~iice~tin(S8~9) 132 
Glicentin(55-69) 108 
~licentin(49-69) 86.2 
Glicentln(37-69) 98.6 
Clicentin(33-69) 
(~XyntamoduIin) 105 
Praglucagon fragment(30-37) 3.45 
Natural peptides 
Olicentin I20 
Glucagon 0 
The relative crossreactivity of each peptide was esti- 
mated by comparing the amounts of the peptide and 
standard glicentin(~69) for 50% inhibition of 
ant&&y binding of the tracer 
2.2. Extraction rrf tissue 
Fresh porcine pancreas (go0 g) was imme~~tely 
frozen and homogenized with a S-fold excess of 
0.1 M acetic acid in an ice bath. The homogenate 
was heated in a boiling water bath for 5 min. After 
cooling, acetic acid was added to a final concentra- 
tion of 0.5 M and the homogenate was centri- 
fuged. The precipitate was washed with a 3-fold 
excess 05 M acetic acid and the supernatant and 
washing were combined and lyophilized; the 
resulting powder was triturated with acetone. 
2.3. Amino acid anaiysis 
Peptide (100 ng) was hydrol~ed in 6 N HCl 
(0.3 ml) at 110°C for 24 h in an evacuated tube. 
The solution was evaporated to dryness and the 
residue submitted to amino acid analysis. 
2.4. Sequence analysis 
Peptide (200 ng) was analyzed according to 
operation programs OlPREP and RUNTFA pro- 
vided for the sequencer. PTH-amino acids 
liberated were identified by HPLC on an 
Ultrasphere column (Beckman Instruments, Palo 
Alto, CA) (2 x 250 mm) heated at 50°C with use 
of a gradient solvent system of aceto~trile/20 mM 
sodium acetate (pH 4.5) (IO: 90, v/v, for O-i min; 
IO:%35:65 for l-3 min; 35~6%40:6O for 
3-18 min; 40: 60 for 18-35 min). The eluates were 
monitored at wavelengths of 260 and 322 nm. 
3. RESULTS 
Glicentin C-terminal hexapeptide-like immuno- 
reactivity in the crude extract of porcine pancreas 
is shown in table 2 together with pancreatic 
glucagon i~unor~~ivity* Acid-alcohol extrac- 
tion was more efficient for pancreatic glucagon; 
hexapeptide immunor~ctivity was extracted with 
dilute acetic acid and compared with glueagon im- 
munoreactivity extracted with acid-alcohol. The 
molar ratio between both immunoreactivities 
(underlined in table 2) was 1: 1.08. 
Fig.I shows a Sephadex G-50 column elution 
profile of hexapeptide-like immunoreactivity from 
the extract. The major immunoreactivity coeluted 
with synthetic glicentin(64-69) and was estimated 
to be 83.2ala of the total hexapeptide-like im- 
munorea~ivity applied. In addition, 2 smaller 
peaks were detected: a very smalI one coeluted with 
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Table 2 
Gkentin- and glucagon-related immunoreactivities in 
crude extracts of porcine pancreas 
Radioimmunoassay Immunorea~tivity 
(fmol eq/mg wet wt 
tissue) 
A B 
Glicentin C-terminal 
hexapeptide specific 
Pancreatic glucagon 
specific 
@2._ 462 
325 J& 
A, extract with hot dilute acetic acid; B, extract with 
arid-~~ohol (see [ 121) 
glicentin (fraction 33) and the other eluted between 
glicentin and glucagon (fraction 42). The latter 
medium-sized peak is very likely to represent 
the 37-residue peptide, oxyntomodulin, whose 
presence in pancreas has been suggested [ 111. Peak 
fractions 48-59 were collected and successively 
fractionated by gel filtration on a Sephadex G-10 
column (fig.2). Combined fractions 25-34 were 
chromato~aphed on an SP-Sephadex C25 column 
(fig.3). The i~unoreactive peak fractions 
(76-89) were desalted with a Sep-Pak Cl8 cartridge 
(Waters Associates, Milford, MA), The material 
was then chromatographed on QAE-Sephadex 
A-25 column (fig.4). Fractions 13-22 were com- 
Fig. 1. Gel filtration of pancreatic crude extract (1 g) on 
Sephadex G-50 medium. Column, 3.1 x 110 cm; 
elution, 3 M AcOH; fraction, 13 g/tube. 
Y 
Fig.2. Sephadex G-10 gel filtration of the material (15 g) 
contained in fractions 48-59 from Sephadex G-JO gel 
filtration. Column, 3.0 x 93 cm; elution, 3 M AcOH; 
fraction, 10 g/tube. 
bined and chromatographed on a Sephadex G-15 
column (fig.5). The immunoreactive component 
eluted in fractions 25-28 was finally purified by 
HPLC on a Nucleosil 5ClS column (M. Nagel, 
Diiren, FRG). A single peak was detected between 
retention time 18 min 25 s and 19 min 15 s by im- 
munoreactivity (frg.6a) which corresponded to the 
main peak when monitored by absorption at 
210 nm (fig.fib). This material was collected and 
found to coelute with synthetic glicentin(64-69) in 
HPLC (fig.7a-c). 
The purified peptide preparation was submitted 
to amino acid and sequence analyses. The results 
are shown in fig.& 
The data clearly indicate that the isolated pep- 
tide was a hexapeptide of the glicentin(64-69) se- 
quence. The yield in each purification step is 
shown in table 3, 
4. DISCUSSION 
We have previously developed a radioim- 
munoassay exclusively specific for the C-terminal 
hexapeptide portion of glicentin (see table 1) and 
demonstrated the existence of a glicentin C- 
terminal hexapeptide-like component in porcine 
pancreas 191. Availability of this highly specific 
radioimmunoassay enabled us to isolate the hex- 
apeptide, glicentin(~-69), from porcine pancreas. 
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Fig.3. Chromatography on SP-Sephadex C25 of the material (3.57 g) obtained from fractions 25- 14 of Sephadex G-10 
gel filtration. Column, 3.0 x 23 cm; elution, 0.005 M AcON&, pH 6.7 (300 ml) followed by a linear gradient with 
0.005 M (1000 ml) and 0.4 M (1000 ml) AcON&, pH 6.7; fraction, 20 g/tube. 
The purification steps for the hexapeptide included 
gel filtration, ion-exchange chromatography and 
HPLC. During the course of purification, the 
chromatographic fractions were monitored by 
radioimmunoassay. In each step, the recovery 
of the desired peptide, radioimmunologically 
estimated from the elution profile, was 
71.4-91.7%. The final yield of the hexapeptide 
was 22pg (4.3%) from 800 g pancreas. The 
hexapeptide-like immunoreactivity measurable by 
the present radioimmunoassay in the crude pan- 
creatic extract corresponded to 92.2% (see table 2), 
-0 
10 20 40 50 60 70 80 
Fraction No. 
Fig.4. Chromatography on QAE-Sephadex A-25 of the 
material (15 mg) obtained from fractions 76-89 of SP- 
Sephadex chromatography. Column, 1.2 x 16 cm; 
elution, 0.01 M Tris-HCl buffer, pH 9.0 (20 ml), 
followed by a linear gradient with 0.01 M Tris-HCl 
buffer, pH 9.0 (175 ml) and the same buffer containing 
0.3 M NaCl (175 ml); fraction, 5 g/tube. 
on a molar basis, of the pancreatic glucagon 
immunoreactivity. The immunoreactivity at- 
tributable to the hexapeptide itself was estimated 
to be 83.2% (see table 3) of the total hexapeptide- 
like immunoreactivity in the crude extract, which 
in turn corresponded to 76.7%, on a molar basis, 
of the pancreatic glucagon immunoreactivity. As a 
result, it seems probable that the hexapeptide and 
glucagon exist in pancreas on an equimolar basis. 
BBA Glicentin@4-69~ vt 
4 4 4 
10 20 50 60 70 
Frection NC. 
Fig.5. Sephadex G-15 gel filtration of the material 
obtained from fractions 13-22 of QAE-Sephadex 
chromatography. Column, 1.9 x 90 cm; elution, 3 M 
AcOH; fraction,4.5 g/tube. 
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Fig.6. Reverse-phase HPLC of the material obtained 
from fractions 25-28 of Sephadex G-15 gel filtration. 
Column, Nucleosil5Cts (4.6 x 250 mm); elution, 0.01 N 
HC!l/C!H3OH (100:0-W: 10, v/v, for 30 min and 
90: 10-50: 50 for 40 mm); flow rate, 1 .O mI/min. The 
fractions collected every 30 s were measured (a) by 
radioimmunoassay and the eluate was monitored (b) by 
absorption at 210 nm. 
No hexapeptide-like component was detected in 
porcine intestinal extracts, which was compatible 
with a previous suggestion on the formation of ox- 
yntomodulin in porcine intestine [12]. These data 
indicate that the processing of pancreatic pro- 
glucagon liberates the hexa~ptide from the glicen- 
tin sequence in a tissue-specific manner during the 
production of glucagon. Moody et al. [ 131 have 
suggested that the glicentin N-terminal 30-residue 
peptide GRPP is a major cleavage product of por- 
cine proglucagon. Our study revealed the C- 
terminal hexapeptide of glicentin as another major 
processing product of the precursor. Lopez et al. 
[3] and Bell et al. 141 have independently proposed 
the biosynthetic pathway for the processing of 
mammalian pancreatic preproglucagon. More 
recently, Patzelt and Schiltz 1141 have also de- 
September 1985 
Fig.7. Identification by reverse-phase HPLC of purified 
peptide with synthetic H-Asn-Lys-Asn-Asn-Ile-Ala-OH. 
CoIumn, Nucleosil SC18 (4.6 x 250 mm); elution, 0.01 N 
HCllCHsOH (100: O-90: 10, v/v, for 30 min and 
90: 10-50: 50 for 40 min); flow rate, 1.0 ml/min; 
detection, 210 nm. (a) Purified peptide (2pg), (b) 
synthetic H-Asn-Lys-Asn-Asn-Ile-Ala-OH (2 ~8) and (c) 
purified peptide (1 pug) + synthetic hexapeptide (1pg). 
scribed the conversion of proglucagon in rat pan- 
creatic A cells. However, all these investigators 
have left the fate of the hexapeptide during pro- 
cessing uncertain. The present isolation of the hex- 
apeptide corresponding to g~~entin(64-69) con- 
Amino acid ratios in acid hydrolysate 
Sequence analysis 
--Lb_.zh&A-A 
Asn-Lys-Asn-Asn-Ile-Ala 
Fig.8. Amino acid sequencing of the purified peptide 
from porcine pancreas. 
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Table 3 
Purification of glicentin C-terminal hexapeptide from porcine pancreas 
Puri~~tion step Material Immuno- Recoveryb Yield Puri~cation 
obtained reactivitya (Ye) WJ) (x) 
@g es) 
ExtractionC 37.2 490 g 100 
Sephadex G-50 6.30 g 262 83.2 53.5 3.2 
Sephadex G-10 3.57 g 186 73.9 38.0 4.0 
SP-Sephadex C25 106 71.4 21.6 - 
Sep-Pak 15 mg 79.5 77.7 16.2 402 
QAE-Sephadex A-25 - 41.6 85.2 8.5 - 
Sephadex G- 15 - . 29.6 73.5 6.0 - 
Nucleosil 5Crs 22pgd 21.0 91.1 4.3 72300 
a Glicentin C-terminal hexapeptide-like immunor~cti~ty (hexapeptide s) 
b Recovery of immunor~cti~ty in the respective step 
’ From 800 g fresh porcine pancreas 
d Calculated from absorption at 210 nm in HPLC by comparison with that of synthetic 
glicentin(64-69) 
firmed the intact formation of the peptide with 
glucagon on proteolytic conversion of proglucagon 
in the pancreas (fig.9). 
We demonstrated [ 151 by an immunohistochem- 
ical protein A-gold technique with the currently 
used antiserum R4804 that glicentin C-terminal 
immunoreactivity was located almost exciusively 
over the peripheral mantle of the tx granules of 
human pancreatic A cells where glicentin N-ter- 
minal immunoreactivity was also demonstrated 
[16]: The present results may suggest that the 
immunoreactivity observed in the peripheral man- 
tle is attributable to the hexapeptide, not glicentin 
or oxyntomodulin, formed as a product of pro- 
teolytic conversion. 
Tager and Steiner 11’71 have reported the se- 
quence of -----an-Asn-Lvs-Asn-Ile-~a-OH for 
the C-terminal sequence of the proglucagon frag- 
Proglucagon 
I 
Proteolytic cleavage 
in pancreas 
Fig.9. Formation of glicentin C-terminal hexapeptide in 
pancreas. 
ment which they had isolated from porcine/bovine 
pancreatic glucagon preparation. Together with 
the putative amino acid sequences of mammalian 
preproglucagon, the present data also confirmed 
the Asn-L~s-an-Asn-Ile-~a sequence for the C- 
terminal extension of glucagon in the precursor 
molecule in porcine pancreas. 
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